kc706
Small moleculeexperimental
Clinical trial activity
1 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00606749)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545282 ↗
Also known as
- kc706
- kc706
- kc-706
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00606749 | Phase 2 | Nov 1, 2007 | Case Western Reserve University, Florida Academic Dermatology Centers, Kemia, Inc, New York University, The University of Texas, Dallas, University of California, Los Angeles, University of North Carolina at Chapel Hill, University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Florida Academic Dermatology Centers | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Kemia, Inc | For profit | 1 | 1 | 1 | 2007 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2007 |
8 organizations
Page 1 / 1